GlaxoSmithKline Submits J-NDAP for Antithrombogenic Agent Fondapariux Sodium.Tokyo, Japan, Nov 25, 2005 - (JCNN JCNN Japan Corporate News Network ) - GlaxoSmithKline (GSK GSK GlaxoSmithKline plc (pharmaceutical company) GSK Glycogen Synthase Kinase GSK Gruppentraining Sozialer Kompetenzen (Germany) GSK Greenland Shark (FAO fish species code) ) announced on November 24 that it has submitted a New Drug Application (J-NDA) to the Ministry of Health, Labor and Welfare, seeking marketing approval of fondapariux sodium. Fondapariux sodium is a selective inhibitor of Factor Xa, a protein central to the coagulation coagulation (kōăg'y  lā`shən), the collecting into a mass of minute particles of a solid dispersed throughout a liquid (a sol), usually followed by the precipitation or process. The company is seeking an indication for venous thromboembolism thromboembolism /throm·bo·em·bo·lism/ (-em´bo-lizm) obstruction of a blood vessel with thrombotic material carried by the blood from the site of origin to plug another vessel. throm·bo·em·bo·lism n. in patients undergoing orthopedic procedures. Initially approved in the US in December 2001, the agent is currently marketed in 30 countries worldwide under the trade name of Arixtra. Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion